1501P - Comparison of the efficacy of filgrastim (Neupogen®) and biosimilar filgrastim (Leucostim®) in patients with chemotherapy-induced neutropenia: A na...

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Complications/Toxicities of Treatment
Supportive Measures
Bioethics, Legal, and Economic Issues
Presenter Alper Sevinc
Citation Annals of Oncology (2014) 25 (suppl_4): iv517-iv541. 10.1093/annonc/mdu356
Authors A. Sevinc1, M. Ozkan2, A. Ozet3, F. Dane4, B. Oksuzoglu5, A. Isikdogan6, F. Ozdemir7, D. Uncu8, M. Gumus9, T. Evrensel10, A. Yaren11, O. Kara12, S.B. Tekİn13
  • 1Medical Oncology Department, Gaziantep University Onkoloji Hastanesi, 27070 - Gaziantep/TR
  • 2Medical Oncology, Erciyes University Medical FacultyM.Kemal Dedeman, Oncology Hospital, TR-38039 - Kayseri/TR
  • 3Medical Oncology, Gazi University Faculty of Medicine, Ankara/TR
  • 4Medical Oncology Department, marmara university hospital, istanbul/TR
  • 5Department Of Medical Oncology, Ankara Dr.A.Y.Oncology Research and Education Hospital, 06200 - ANKARA/TR
  • 6Medical Oncology, Dicle University, 21280 - diyarbakir/TR
  • 7Medical Oncology Dept., Karadeniz Technical UniversityMedical Faculty, TR-61080 - Trabzon/TR
  • 8Medical Oncology, Ankara Numune Education and Research Hospital, ANKARA/TR
  • 9Dept. Medical Oncology, Bezmialem Vakif University Hospital, 34093 - Istanbul/TR
  • 10Medıcal Oncology, Uludag University Medıcıne Faculty, 16059 - Bursa/TR
  • 11Medical Oncology, Pamukkale University School of Medicine, 20070 - Denizli/TR
  • 12Medical Oncology, Cukurova University Medical Faculty, 01330 - Adana/TR
  • 13Medical Oncology, Ataturk University, 25070 - ERZURUM/TR



A biosimilar drug is an analogous drug of the biological licensed referenced drug. In this cohort, we aimed to study the effectiveness of the biosimilar and origial filgrastim in patients with chemotherapy-induced neutropenia.


There were 337 patients in the national observational study. Patients receiving chemotherapy was enrolled in the study after neutropenia. Filgrastim, either original or biosimilar, was used.


The average age was 53.15 ± 14.10 years, the median was 55.0 (min:19-max:85) years. There were 724 courses of drug application. 13.7% received one course of chemotherapy (CT), 45.5% received two courses of CT, 27.4% received three courses of CT, 11.4% received four courses of CT, and the rest received five courses of CT. The avarage neutrophil count was 0.4 before the filgrastim application and 3.0 afterwards. Biosimilar filgrastim 30 was applied to 61.9%, original filgrastim 30 to 8.9%, and original filgrastim 48 to 29.2%. Recovery in four days was observed in 60.1% of the patients receiving biosimilar filgrastim 30, 56.7% in original filgrastim 30, and 52.6% in original filgrastim 48. However, there was no statistically significant difference in the neutropenia recovery periods for all of the drugs (p > 0,05). There was also no statistically significant difference between biosimilar filgrastim 30 vs. original filgrastim 30 in the recovery periods (p > 0.05).


The biosimilar drug should be compared with the original drug in order to establish the same efficacy. The present study did not find any difference between the biosimilar and original filgrastim in patients with chemotherapy-induced neutropenia.


All authors have declared no conflicts of interest.